Bernstein analyst Eve Burstein lowered the firm’s price target on Illumina (ILMN) to $140 from $145 and keeps a Market Perform rating on the ...

Illumina has begun rolling out a series of updates to its top-of-the-line DNA sequencer models, with the goal of making the ...

Illumina, Inc. ILMN has announced a series of updates to its NovaSeq X Series. The company’s single-flow-cell NovaSeq X Sequencing System is now available for the first time, alongside the software v1 ...

ClariMed, Inc., a global leader in human-centered medical device development and regulatory services, has announced the ...

MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into a clinical supply ...

Illumina (ILMN) announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow-cell system alongside a software ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of ...

Read Our Latest Stock Analysis on Illumina Illumina Trading Down 0.9 % Illumina stock opened at $143.12 on Wednesday. Illumina, Inc. has a 52-week low of $100.08 and a 52-week high of $156.66. The ...

How Illumina's Erin Imsand and her team helped ... about a project still in the concept stage-what would become the NovaSeq X. She was asked to help incorporate lyophilization (better known ...